HeartSciences seeks to bridge today’s “diagnostic gap” in cardiac care by providing effective front-line solutions that assist in the detection of heart disease in at-risk patients. HeartSciences has invested years of R&D focused on advancing the field of electrocardiography through the use of technology to develop new algorithms focused on detecting cardiac conditions not previously available in ECG devices. HeartSciences’ MyoVista® Wavelet ECG (wavECG™) Cardiac Testing Device uses an advanced form of signal processing called continuous wavelet transform (CWT) to extract valuable frequency information from the acquired signal and then analyzes this information using artificial intelligence to provide new information related to a patient’s risk for left ventricular abnormalities. MyoVista wavECG Technology focuses on the recent understanding that most forms of heart disease are associated with left ventricular (LV) relaxation abnormalities and diastolic dysfunction.
Formed in 2008, HeartSciences (formerly known as Heart Test Laboratories) is a privately held medical technology company located in the Dallas-Fort Worth metroplex.